- Home
- KALV vs IIIV Comparison
KALV vs IIIV Comparison
Compare KALV & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- IIIV
- Stock Information
- Founded
- KALV N/A
- IIIV 2012
- Country
- KALV United States
- IIIV United States
- Employees
- KALV N/A
- IIIV N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- KALV Health Care
- IIIV Technology
- Exchange
- KALV Nasdaq
- IIIV Nasdaq
- Market Cap
- KALV 637.9M
- IIIV 707.2M
- IPO Year
- KALV N/A
- IIIV 2018
- Fundamental
- Price
- KALV $12.34
- IIIV $31.69
- Analyst Decision
- KALV Strong Buy
- IIIV Buy
- Analyst Count
- KALV 9
- IIIV 7
- Target Price
- KALV $26.29
- IIIV $29.57
- AVG Volume (30 Days)
- KALV 1.0M
- IIIV 307.6K
- Earning Date
- KALV 09-04-2025
- IIIV 08-07-2025
- Dividend Yield
- KALV N/A
- IIIV N/A
- EPS Growth
- KALV N/A
- IIIV N/A
- EPS
- KALV N/A
- IIIV 5.56
- Revenue
- KALV N/A
- IIIV $248,271,000.00
- Revenue This Year
- KALV N/A
- IIIV N/A
- Revenue Next Year
- KALV $192.67
- IIIV $5.07
- P/E Ratio
- KALV N/A
- IIIV $7.71
- Revenue Growth
- KALV N/A
- IIIV 9.06
- 52 Week Low
- KALV $7.30
- IIIV $20.42
- 52 Week High
- KALV $16.32
- IIIV $32.33
- Technical
- Relative Strength Index (RSI)
- KALV 36.00
- IIIV 74.13
- Support Level
- KALV $12.19
- IIIV $27.70
- Resistance Level
- KALV $14.35
- IIIV $32.33
- Average True Range (ATR)
- KALV 0.61
- IIIV 0.84
- MACD
- KALV -0.30
- IIIV 0.21
- Stochastic Oscillator
- KALV 5.26
- IIIV 88.66
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.